The JV, Amgen-Beta Pharmaceuticals Co., will focus on the commercialization of Amgen's colorectal cancer drug, Vectibix, in China.

As some firms want to make and sell drugs similar to biological medicines made by the likes of Amgen and Genentech, a measure aims to regulate their use.SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on ...

TBIO: Q1 Revenue In-Line. Amgen Deal Is Encouraging

Amgen (NASDAQ: AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.

Amgen really needs the pipeline to come through to support this valuation.